Cel Sci Corporation (CVM)

[Spideyboy]

I would agree with FM as far as the investment is concerned.

If executed, and I feel likely, the R/S almost without fail will bring the value down, admittedly they have until mid 2018 I think before really needing to force that card, and in the meantime there are events already discussed and other unknowns that could help minimise the need or impact of the R/S.

Also, while not having the clinical data I feel that deciding to drop the new sample, while helping to speed up the completion of the trial, this may not be the wisest thing to do vis-a-vis maximising the chance of getting the data needed for approval. So I'm not looking at the dropping of extra sample as positive at the moment. Perhaps the data already looks good and I'm wrong, but more data points is usually the better way to go and there must have been a reason for bringing them on in the first place.

However with regards the timeline for Arb, I'm quite certain Geert is talking the second quarter as in calendar year, thus expecting the outcome of Arb by end of this June.

So a letter that still leaves the stock with little concrete clarity, keeping the content open to interpretation as pros and/or cons. Though I do agree the tone seems in a positive light, and at least there finally is some-sort of communication.

Still long CVM